(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
15 December 2016 (15.12.2016)

WIPO | PCT

(10) International Publication Number
WO 2016/199140 A8

(51) International Patent Classification:
*A61K 39/00* (2006.01) *C07K 16/30* (2006.01)
*A61P 35/00* (2006.01) *C07K 16/40* (2006.01)
*C07K 16/28* (2006.01)

(21) International Application Number:
PCT/IL2016/050599

(22) International Filing Date:
8 June 2016 (08.06.2016)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/172,264 8 June 2015 (08.06.2015) US
N2014935 8 June 2015 (08.06.2015) NL

(71) Applicant: **ADICET BIO INC.**; 200 Constitution Drive, Menlo Park, CA 94025 (US).

(72) Inventors: **PELED KAMAR, Mira**; 7 Shalonski Street, 4676707 Herzlia (IL). **DENKBERG, Galit**; 63 Gilboa Street, 3600100 Nofit (IL). **REITER, Yoram**; 23 Esther Rabin Street, 3498784 Haifa (IL). **BEER, Ilan**; 3 Petel Street, 3455614 Haifa (IL). **SINIK, Keren**; 60 HaTzavim Street, 3009500 Ramat-Yishai (IL). **TEBOUL (ELBAZ), Yael**; 10 Hasidey Umot HaOlam Street, 3298523 Haifa (IL). **SHPERBER (SERY), Yael**; 87 Snir Street, 2514700 Kfar-Vradim (IL). **EREL SEGAL, Reut**; 5/16 Shlomo Goren Street, 2650316 Haifa (IL). **OREN, Ravit**; 37 Beit Alfa Street, 2622153 Haifa (IL). **ALISHEKEVITZ, Dror Shmuel**; 77 Tamar Street, 3653405 Kiryat-Tivon (IL).

(74) Agents: **EHRLICH, Gal** et al.; G.E. Ehrlich (1995) LTD., 11 Menachem Begin Road, 5268104 Ramat Gan (IL).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17**:

— *of inventorship (Rule 4.17(iv))*

**Published**:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(48) Date of publication of this corrected version:
29 December 2016

(15) Information about Correction:
see Notice of 29 December 2016

(54) Title: T CELL RECEPTOR LIKE ANTIBODIES HAVING FINE SPECIFICITY

(57) Abstract: An antibody capable of binding, with a human major histocompatibility complex (MHC)-restricted specificity, a MHC being complexed with an HLA-restricted peptide antigen is provided. The antibody having a binding specificity dictated by at least 4 amino acid residues in said HLA-restricted peptide such that at least 70 % reduction in binding of said antibody to said complex is observed when each of said at least 4 amino acid residues is substituted as determined by FACS of cells loaded with said HLA- estricted peptide comprising said substitution, said at least 4 amino acid residues not being anchor residues.

WO 2016/199140 A8